

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **MBV INTERNATIONAL LIMITED**

### **中國大人國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1957)**

## **VOLUNTARY ANNOUNCEMENT**

This announcement is made by MBV International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

Lordan Group Ltd. (together with its subsidiaries, “**Daren Group**”) is an associate of the Group. The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 19 June 2024, Daren Group entered into a corporate acquisition intention contract (the “**Acquisition Contract**”) with Beijing Yulong Shengshi Biotechnology Co., Ltd. # (北京昱龍盛世生物科技有限公司) (“**BYS Biotech**”), pursuant to which Daren Group agrees to acquire 51% of the equity interest in BYS Biotech (the “**Acquisition**”). The completion of the Acquisition will take place within two to three months from the date of the Acquisition Contract.

BYS Biotech is a company established in the People’s Republic of China (the “**PRC**”) with limited liability. As at the date of this announcement, Ms. Zhang Xiaonan owns a substantial majority of the equity interest and is the ultimate beneficial owner of BYS Biotech. BYS Biotech is principally engaged in the business of conducting clinical research and application of cell therapy, including treatment of neurological diseases, diabetes and its complications, cancer, heart disease, as well as related technologies and consulting services for sub-health repair and anti-aging of the body.

Daren Group is principally engaged in the business of provision of services in digitalisation and e-commerce transformation of physical businesses in the PRC, covering major cities in the PRC such as Beijing, Hangzhou, Xiamen and Guangzhou, as well as sectors such as local lifestyle services and comprehensive healthcare. If the Acquisition materializes, the Board considers that the Acquisition will help Daren Group to broaden its scope of business and diversify such business portfolio and therefore may increase the Group’s investment return in Daren Group and the return to the Shareholders as a whole in the long run.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**MBV International Limited**  
**Dato' Tan Meng Seng**  
*Chairman and Executive Director*

Hong Kong, 20 June 2024

*As at the date of this announcement, the executive Directors are Dato' Tan Meng Seng, Dato' Tan Mein Kwang, Mr. Tan Beng Sen, Datin Kong Siew Peng and Ms. Hou Yanli; and the independent non-executive Directors are Ms. Chui Sin Heng, Mr. Au Wing Yuen and Mr. Yu Cheeric.*

# *The English transliteration of the Chinese names in this announcement, where indicated, is included for information only, and should not be regarded as the official English names of such Chinese names.*